Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology Strategies

Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology Strategies is organized by Physicians' Education Resource LLC (PER) and will be held from Jul 30, 2018 - Jul 30, 2019.

The target audience for this medical event is directed toward urologists, oncologists, and researchers interested in the treatment of bladder cancers. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with bladder cancers are invited to participate. This CME Conference has been approved for a maximum of 1.0 Credit.

Description:
Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology Strategies is an online activity based on the live symposium held adjunct to the annual urology meeting in San Francisco. Clinical decision making in the setting of bladder cancer has dramatically changed over recent years with the approvals of several immuno-oncology agents that have improved patient outcomes. Their introduction has raised some clinical questions and challenges regarding optimal treatment selection, duration of treatment, sequencing, as well as identification and management of pseudoprogression and unique toxicities. Use of these agents across multiple lines of therapy for advanced bladder cancer and the potential expansion of their use to early-stage disease makes it imperative that urologists, as members of the multidisciplinary care team, understand both new data and best practices related to the use of immuno-oncology strategies, including proactively monitoring, mitigating, and managing immune-related adverse events. This interactive symposium will bring together a multidisciplinary faculty of renowned experts in urology, medical oncology, and immune-oncology to review practice-changing data and discuss their impact on patient care. Brief didactic presentations will be followed by “real-world” clinical case presentations and discussions that facilitate interpretation and application of the evidence. The faculty will also share their forward-looking perspectives on the bladder cancer treatment horizon based on recently reported and anticipated clinical trial data

Learning Objectives:
At the conclusion of this activity, participants should be better prepared to:
• Explain the mechanistic rationale that underlies the investigation and clinical development of immunotherapeutic approaches to manage bladder cancer
• Evaluate pivotal trial findings from studies that have evaluated immunotherapies for the management of patients with bladder cancer and emerging information concerning the role of biomarkers, combination strategies, and adjuvant approaches in this regard
• Place practice-changing evidence concerning the management of bladder cancer in the context of managing these patients in contemporary urological cancer care settings
• Identify and proactively mitigate the impact of treatment-related toxicities among patients with bladder cancer